
Hecla Mining Company (NYSE: HL) Salt Lake City Keynote Speaker Luncheon
Limited Seating for this private event so please sign up to reserve your seat today!
Limited Seating for this private event so please sign up to reserve your seat today!
Limited Seating for this private event so please sign up to reserve your seat today!
Limited Seating for this private event so please sign up to reserve your seat today!
Limited Seating for this private event so please sign up to reserve your seat today!
Fate Therapeutics (NASDAQ: FATE) is developing clinical-stage cellular immunotherapies for cancer and immune disorders, with an opportunity in 2017 to broadly establish the leading NK (natural killer) cell clinical franchise. The Company’s programs include:
The Company raised $57 million in Nov 2016 from a leading investor syndicate including Redmile Group LLC, BVF Partners L.P., EcoR1 Capital LLC, and Franklin Advisers, Inc., and had approximately $100 million in cash following the financing. Institutional ownership exceeds 70%.